Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1137020090200020117
Journal of Gynecologic Oncology
2009 Volume.20 No. 2 p.117 ~ p.121
Expression and mutational analysis of TGF-?/Smads signaling in human cervical cancers
Ki Kyung-Do

Tong Seo-Yun
Huh Chu-Yeop
Lee Jong-Min
Lee Seon-Kyung
Chi Sung-Gil
Abstract
Objective: To define the molecular basis of TGF-?1 function in cervical carcinogenesis, we explored the expression and mutational status of TGF-?1, TGF-?1 receptors, and Smads, the regulators of the TGF-?1 signaling pathway, in human cervical cancers.

Methods: Expression of TGF-?1, TGF-?1 receptors, and Smads transcripts were determined by quantitative reverse transcription-polymerase chain reaction (RT-PCR), and sequence alteration was analyzed using RT-PCR-single-strand conformation polymorphism (SSCP) analysis. Genomic levels of TGF-?1, TGF-?1 receptors and Smads was also measured by quantitative genomic PCR.

Results: Abnormal overexpression of TGF-?1 and abnormal reduction of type II TGF-?1 receptor were identified in 36% (18 of 50) and 20% (10 of 50) of cervical cancer tissues, respectively. 22% (11 of 50) in Smad2 and 14% (7 of 50) in Smad4 revealed tumor specific mRNA reduction less than a half of normal means. In addition, no evidence for sequence alterations of the gene was found by RT-PCR-SSCP analysis.

Conclusion: Our study demonstrates that disruption of TGF-?/Smad signaling pathway exist in human cervical cancer, suggesting that abnormal expressions of the member of TGF-?/Smad signaling pathway might contribute to the malignant progression of human cervical tumors via suppressing the tumor suppression function of TGF-?1 1¡¯s tumor suppression function.
KEYWORD
TGF-?/Smads, Cervical cancer, Expression
FullTexts / Linksout information
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø